Last Updated: May 23, 2026

Litigation Details for Entropic Communications, LLC v. DISH Network Corporation (C.D. Cal. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Entropic Communications, LLC v. DISH Network Corporation
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation summary and analysis for: Entropic Communications, LLC v. DISH Network Corporation (C.D. Cal. 2023)

Last updated: April 24, 2026

Entropic Communications, LLC v. DISH Network Corporation (D. Nev.) — Litigation Summary and Patent-Strategy Analysis (2:23-cv-01043)

What case is this and where is it filed?

Entropic Communications, LLC sued DISH Network Corporation in the U.S. District Court for the District of Nevada.

  • Case: Entropic Communications, LLC v. DISH Network Corporation
  • Docket: 2:23-cv-01043
  • Filing posture: Patent litigation (complaint filed in 2023; case proceeds in federal court)

What claims does the plaintiff press?

Insufficient information available in the provided record to identify the asserted patents, claim counts, or the specific infringement theories for this docket. A complete litigation analysis requires the asserted patent list and the asserted claim mapping structure (device-level elements, method steps, or system components), which is not present in the supplied materials.

What do the pleadings typically include in this posture?

In federal patent suits like this, the standard case architecture is:

  • Complaint: asserted patents, infringement allegations, and an infringement “basis” narrative
  • Responsive pleading: defenses that commonly include non-infringement and invalidity categories (anticipation/obviousness, lack of written description/enablement, indefiniteness), plus procedural defenses
  • Claim construction: Markman phase to lock claim terms
  • Expert discovery: damages theories, technical infringement analyses
  • Potential motion practice: venue, stay requests (if PTAB proceedings exist), early motions on pleadings, claim construction motions, Daubert

However, this specific case’s actual asserted patents, defenses, and any PTAB or Markman milestones are not contained in the provided information, so a fact-anchored summary of positions, dates, or outcomes cannot be produced.

What is the litigation timeline?

Insufficient information available to produce a complete and accurate docket timeline (including key dates such as service, responsive motions, initial disclosures schedule, Markman scheduling order, and any dispositive orders). A litigation summary at Bloomberg-grade precision must cite the order entries and dates from the docket, which are not included in the provided record.

How do courts in this district typically handle core patent issues?

Without the case-specific order text, the best we can do is state the issues that normally drive outcomes in District of Nevada patent cases:

  • Claim construction: resolving meaning of disputed claim terms before merits discovery maturation
  • Infringement element matching: correlating accused features to each asserted claim limitation
  • Invalidity under 35 U.S.C. §§ 102/103: prior art combinations and motivation/reasoning for obviousness
  • Indefiniteness and § 112: claim scope clarity and specification support
  • Damages: reasonable royalty framework and whether proof aligns with claim scope

This does not provide case-specific conclusions for this docket.

What is the patent-portfolio and product-risk framing?

A patent-risk analysis requires the asserted patents and the accused DISH product set. Without:

  • the asserted patent numbers
  • the claim focus (e.g., RF communication method claims vs. encoder/decoder processing vs. provisioning)
  • the accused DISH technology architecture referenced in the complaint

a defensible assessment of risk, likely contention points, or design-around feasibility cannot be completed.

What defenses does DISH typically raise in these cases?

Common DISH-type defenses in modern patent litigation (industry-wide, not docket-confirmed here) include:

  • Non-infringement: lack of particular system elements or steps
  • Invalidity: anticipation/obviousness based on prior art disclosures and combinations
  • Subject-matter or claim-quality defenses: § 101 where applicable; § 112 written description/enablement; indefiniteness
  • Procedural defenses: jurisdictional or venue challenges when present

But none of these can be tied to the actual DISH positions in 2:23-cv-01043 without the pleadings or order content.

What is the likely procedural posture (and what matters next)?

For a complete case-path forecast, the next decisional fork points are usually:

  • Markman date and claim construction scope: constricted claim scope often drives summary judgment and damages recalibration
  • PTAB relationship: IPRs can shift leverage if institution occurs
  • Early summary judgment motions: invalidity on discrete grounds or non-infringement of specific limitations

Again, this case-specific sequencing cannot be produced without docket entries and filings.

Can this matter be evaluated for settlement dynamics?

Settlement dynamics depend on:

  • strength of asserted claims and prosecution history
  • how well accused products map to claim elements
  • damages exposure (royalty base, sales scope, comparable licenses)
  • litigation pace and Markman/claim-construction outcomes
  • concurrent PTAB litigation outcomes

None of those inputs are available in the supplied record, so a calculation-grade settlement valuation cannot be produced.


Key Takeaways

  • The case identifier is Entropic Communications, LLC v. DISH Network Corporation, 2:23-cv-01043 (D. Nev.).
  • A complete litigation summary and patent-strategy analysis requires the asserted patents, claim sets, infringement theories, defenses, and docket milestones, none of which are included in the provided information.
  • No case-specific positions (e.g., invalidity grounds, Markman outcomes, claim-construction results, dispositive rulings) can be stated accurately without the underlying docket documents.

FAQs

  1. What court and docket number is this?
    District of Nevada; 2:23-cv-01043.

  2. Who are the parties?
    Entropic Communications, LLC (plaintiff) and DISH Network Corporation (defendant).

  3. What patents are asserted?
    Not specified in the provided record.

  4. What is the current procedural stage?
    Not specified in the provided record.

  5. What is the best next-step for assessing litigation risk?
    Identify the asserted patent numbers and obtain claim construction and any PTAB status; those drive merits and damages.


References

[1] United States District Court for the District of Nevada. Entropic Communications, LLC v. DISH Network Corporation, No. 2:23-cv-01043. (Case docket information).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.